IPG11406
Small molecule
IPG11406 is one of 33 small molecule programs targeting Lupus Nephritis. It is currently in development.
1
Indications
2
Total Trials
2
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
154 competitors in Lupus Nephritis
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Gazyva
RochePhase 3
Orencia
Bristol-Myers SquibbPhase 3
Myfortic
NovartisPhase 3
Arava
SanofiPhase 3
Cosentyx
NovartisPhase 3
Saphnelo
AstraZenecaPhase 3
Rayos
RRoxane Laboratories
Phase 3
Keytruda
Merck & Co.Phase 3
Cellcept
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IPG11406. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]